scholarly journals The Predictive role of Neutrophil-to-Lymphocyte Ratio (NLR) and Mean Platelet Volume-to-Lymphocyte Ratio (MPVLR) for Cardiovascular Events in Adult Patients with Acute Heart Failure

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Teeranan Angkananard ◽  
Teeraporn Inthanoo ◽  
Suchat Sricholwattana ◽  
Nattapun Rattanajaruskul ◽  
Arthit Wongsoasu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Mean Platelet Volume ◽  
Cardiovascular Events ◽  
Hospital Death ◽  
Composite Outcome ◽  
Platelet Volume ◽  
Lymphocyte Ratio ◽  
Predictive Role

Introduction. The inflammatory response plays a potential role for the pathogenesis and adverse outcomes of heart failure (HF). We aimed to explore the predictive role of baseline neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume-to-lymphocyte ratio (MPVLR) on cardiovascular events (CVEs) in patients hospitalized with acute HF. Materials and Methods. A retrospective cohort study was conducted in 321 patients with HF between January 2017 and December 2019. The association between their NLR, MPVLR, and combined NLR and MPVLR and CVEs, rehospitalization for HF, in-hospital death, and a composite outcome was explored by survival analysis using a Cox proportional hazard model. They were separately investigated and compared with the area under the receiver operating characteristics curve (AUC). Results. Up to the end of the 3-year follow-up, 96 (29.9%) had CVEs, 106 (33.0%) died, 62 (19.3%) were rehospitalized with HF, and 21 (6.5%) died during admission. The NLR and MPVLR were significantly associated with CVEs (adjusted HR for NLR ≥ 3.29 , 3.11; 95% CI, 1.98-4.89; MPVLR ≥ 8.57 , 2.86; 95% CI, 1.87-4.39), readmissions for HF (adjusted HR for NLR ≥ 3.58 , 2.70; 95% CI, 1.58-4.61; MPVLR ≥ 6.43 , 2.84; 95% CI,1.59-5.07), in-hospital mortality (adjusted HR for NLR ≥ 3.29 , 9.54; 95% CI, 2.19-41.40; MPVLR ≥ 8.57 , 7.87; 95% CI, 2.56-24.19), and composite outcome (adjusted HR for NLR ≥ 3.32 , 4.76; 95% CI, 3.29-6.89; MPVLR ≥ 7.07 , 3.64; 95% CI, 2.58-5.15). The AUC of NLR and MPVLR for CVEs were 0.67 (95% CI, 0.61-0.72) and 0.63 (95% CI, 0.58-0.69). Combined NLR and MPVLR increased the AUC to 0.77 (95% CI, 0.72-0.83) with statistical significance. Conclusion. The elevated NLR and MPVLR on admission in patients with acute HF were independently associated with worse CVEs, rehospitalization for HF, in-hospital death, and composite outcomes. These economical biomarkers should be considered in the management and follow-up care of patients with acute HF.

scholarly journals The role of the mean platelet volume and neutrophil-to-lymphocyte ratio in peritonsillar abscesses

2016 ◽  
Vol 82 (6) ◽  
pp. 662-667 ◽  
Author(s):  
Mehmet Şentürk ◽  
İsa Azgın ◽  
Gültekin Övet ◽  
Necat Alataş ◽  
Betül Ağırgöl ◽  
...  
Keyword(s):  
Mean Platelet Volume ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet Volume ◽  
Lymphocyte Ratio ◽  
The Mean

scholarly journals Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients

2021 ◽  
Author(s):  
Marta Ragonese ◽  
Gianluca Di Bella ◽  
Federica Spagnolo ◽  
Loredana Grasso ◽  
Angela Alibrandi ◽  
...  
Keyword(s):  
Heart Failure ◽  
General Population ◽  
Brain Natriuretic Peptide ◽  
Roc Curve ◽  
Cardiovascular Events ◽  
Roc Analysis ◽  
Middle Term ◽  
Increased Risk

Abstract Background Acromegaly is associated with an increased risk of fatal and non-fatal cardiovascular (CV) events. Controlling acromegaly decreases, but does not normalize this risk. Brain natriuretic peptide (BNP) assessment is used in the general population for the diagnosis of heart failure and to predict ischemic recurrences and mortality. This is a retrospective, longitudinal, monocenter study that evaluates the role of serum N-terminal fragment of BNP (NT-pro-BNP) for predicting CV events in acromegaly patients. Methods Serum NT-pro-BNP levels were measured in 76 patients with acromegaly (23 males, 57.7±1.5 years), and compared with other predictors of CV events. NT-pro-BNP cut-off value discriminating the occurrence of CV events was determined by ROC analysis. CV events were recorded during a follow-up of 78.6±6.4 months. Results CV events occurred in 9.2% of patients. Mean log(NT-pro-BNP) concentration was higher in patients who experienced CV events than in those who did not (p<0.01) and in patients who died due to CV events than in those who died due to other causes (p<0.01). Based on the ROC curve, a cut-off value of 91.55 pg/mL could predict CV events (OR 19.06). Log(NT-pro-BNP) was lower in surgically treated patients by surgery (p<0.05), and in those cured by neurosurgery (p<0.02). Conclusions High NT-pro-BNP value is an independent middle-term predictor of fatal or non-fatal CV events in patients with acromegaly. According to this parameter, surgically treated patients show lower CV risk than those managed with medical therapy, especially if the disease is cured.

scholarly journals Clinical significance and prospects of using ST2 in isсhemic heart failure patients

2020 ◽  
Vol 35 (2) ◽  
pp. 89-97
Author(s):  
E. V. Grakova ◽  
K. V. Kopeva ◽  
A. T. Teplyakov ◽  
A. V. Svarovskaya ◽  
O. N. Ogurkova ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cardiovascular Events ◽  
Roc Analysis ◽  
Non Invasive ◽  
Group 2 ◽  
Traditional Risk Factors ◽  
Group 1

Objective: The objective of this study is to assess the role of soluble ST2 (sST2) in developing adverse cardiovascular events (ACE) and fatal outcomes in patients with chronic heart failure (HF) during 18 [12.5; 35.5]-month follow-up period.Results. Depending on the median of baseline sST2 levels, all patients were retrospectively divided into two groups: group 1 enrolled patients with sST2 levels < 31.5 ng/mL (n = 22); and group 2 comprised patients with sST2 levels ≥ 31.5 ng/mL (n = 26). In group 1, the sST2 levels were 27.27 [23.94; 29.23] ng/mL, which was 33.9% higher (p < 0.0000001) than in group 2 (41.28 [34.86; 50.17] ng/mL). ACEs were registered in 9 cases (40.9%) in group 1 and in 17 cases (65.4%) in group 2 (p = 0.025). Based on ROC-analysis, baseline ST2 levels ≥ 33.53 ng/mL were considered a biomarker to predict an unfavorable course of ischemic heart failure during 18 [12.5; 35.5] months of follow-up period with sensitivity of 78.9% and specificity of 62.2% (AUC 0.719; 95% CI 0.562–0.845; p = 0.0059).Conclusion. The baseline sST2 levels may be considered a non-invasive biomarker allowing to predict the development of adverse cardiovascular events (ACE) and fatal outcomes in patients with chronic heart failure (HF) during 18 [12.5; 35.5] months of follow-up in addition to traditional risk factors.

Sign in / Sign up

Export Citation Format

Share Document